About the speaker: Amy Lam joined Edinburgh BioQuarter in November 2011 as part of the Business Development team, with the objective of facilitating commercial engagement of the research base with pharma and biotech and supporting the commercialization of technologies arising from the College of Medicine and Veterinary Medicine at the University of Edinburgh and NHS Lothian. The Business Development team work with academic scientists, clinicalv practitioners and health professionals to develop deeper links with industry, to collaborate and accelerate the development of new drugs, diagnostic tools and medical devices to diagnosev and treat diseases. Prior to her role at BioQuarter, Amy has held a number of positions specializing in the commercialization of technologies in the life sciences sector since 2001. Amy has worked in academia and in industry (AstraZeneca and Eli Lilly) both in the UK and the USA. Originally a pharmacologist by training Amy subsequently studied for a PhD in Neuroscience where her research focused on understanding the role of certain glutamate receptors in stroke. She also has a Master degree in IP Law. Amy currently heads up the Business Development team at Edinburgh BioQuarter.